Silybin Alleviates Experimental Autoimmune Encephalomyelitis by Suppressing Dendritic Cell Activation and Th17 Cell Differentiation

Yang, Huan-Li; Shi, Xiaowu

doi:10.3389/fneur.2021.659678

Cited by 8 publications

(3 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In IFN-ß-treated multiple sclerosis patients, SM was demonstrated to suppress Th1 proliferating activity associated with the inhibition of T-bet gene expression and IFN-γ production by the immune cells [155]. In an animal model of multiple sclerosis, SB was illustrated to decrease DC activation and to suppress pathogenic Th17 inflammatory cell responses, significantly attenuating inflammation and demyelination of the central nervous system in experimental mice [156]. Importantly, SM treatment was found to mitigate virus-induced increased pro-inflammatory cytokine production and liver inflammation in a mouse model of Mayaro virus infection [157].…”

Section: Other In Vivo Model Systems and Disease Statesmentioning

confidence: 99%

Silymarin and Inflammation: Food for Thoughts

Surai,

Earle-Payne

2024

Antioxidants

View full text Add to dashboard Cite

Inflammation is a vital defense mechanism, creating hostile conditions for pathogens, preventing the spread of tissue infection and repairing damaged tissues in humans and animals. However, when inflammation resolution is delayed or compromised as a result of its misregulation, the process proceeds from the acute phase to chronic inflammation, leading to the development of various chronic illnesses. It is proven that redox balance disturbances and oxidative stress are among major factors inducing NF-κB and leading to over-inflammation. Therefore, the anti-inflammatory properties of various natural antioxidants have been widely tested in various in vitro and in vivo systems. Accumulating evidence indicates that silymarin (SM) and its main constituent silibinin/silybin (SB) have great potential as an anti-inflammation agent. The main anti-inflammatory mechanism of SM/SB action is attributed to the inhibition of TLR4/NF-κB-mediated signaling pathways and the downregulated expression of pro-inflammatory mediators, including TNF-α, IL-1β, IL-6, IL-12, IL-23, CCL4, CXCL10, etc. Of note, in the same model systems, SM/SB was able to upregulate anti-inflammatory cytokines (IL-4, IL-10, IL-13, TGF-β, etc.) and lipid mediators involved in the resolution of inflammation. The inflammatory properties of SM/SB were clearly demonstrated in model systems based on immune (macrophages and monocytes) and non-immune (epithelial, skin, bone, connective tissue and cancer) cells. At the same time, the anti-inflammatory action of SM/SB was confirmed in a number of in vivo models, including toxicity models, nonalcoholic fatty liver disease, ischemia/reperfusion models, stress-induced injuries, ageing and exercising models, wound healing and many other relevant model systems. It seems likely that the anti-inflammatory activities of SM/SB are key elements on the health-promoting properties of these phytochemicals.

show abstract

Section: Other In Vivo Model Systems and Disease Statesmentioning

confidence: 99%

Silymarin and Inflammation: Food for Thoughts

Surai,

Earle-Payne

2024

Antioxidants

View full text Add to dashboard Cite

show abstract

“…Silybin reduced also the expression of costimulatory molecules (e.g., CD80 and CD86) and MHC II in bone marrow-derived DCs (BM-DCs). 92…”

Section: Neuroprotective Activitymentioning

confidence: 99%

Silybin and its congeners: from traditional medicine to molecular effects

Křen

Valentová

2022

Nat. Prod. Rep.

View full text Add to dashboard Cite

show abstract

“…In agreement with these studies, we previously showed that Silibinin upregulates ERβ expression, induces apoptosis, inhibits proliferation, and reduces expression of the pro-inflammatory cytokines through ERβ binding in T lymphocytes from female and male healthy donors and patients with active Rheumatoid Arthritis [ 10 ]. Moreover, Silibinin has been also shown immunosuppressive effects in experimental autoimmune encephalomyelitis (EAE), the animal model of multiple sclerosis via inhibition of dendritic cell (DC) activation, and Th17 cell differentiation [ 11 ]. Silibinin has also been demonstrated to inhibit phenotypic and functional maturation of murine bone marrow-derived DC and Th1 polarization.…”

Section: Introductionmentioning

confidence: 99%

Human Monocyte-Derived Dendritic Cells Are the Pharmacological Target of the Immunosuppressant Flavonoid Silibinin

Pagano¹,

Fecchi²,

Pierdominici³

et al. 2022

IJMS

View full text Add to dashboard Cite

Silibinin, a natural polyphenolic flavonoid, is known to possess anti-inflammatory, anticancer, antioxidant, and immunomodulatory properties. However, the effects of Silibinin on the maturation and immunostimulatory functions of human dendritic cells (DC) remain to be elucidated. In this study, we have attempted to ascertain whether Silibinin influences the maturation, cytokine production, and antigen-presenting capacity of human monocyte-derived DC. We show that Silibinin significantly suppresses the upregulation of costimulatory and MHC molecules in LPS-stimulated mature DC and inhibits lipopolysaccharide (LPS)-induced interleukin (IL)-12, IL-23, and TNF-α production. Furthermore, Silibinin impairs the proliferation response of the allogenic memory CD4 T lymphocytes elicited by LPS-matured DC and their Th1/Th17 profile. These findings demonstrate that Silibinin displays immunosuppressive activity by inhibiting the maturation and activation of human DC and support its potential application of adjuvant therapy in the treatment of autoimmune diseases.

show abstract

Silybin Alleviates Experimental Autoimmune Encephalomyelitis by Suppressing Dendritic Cell Activation and Th17 Cell Differentiation

Cited by 8 publications

References 32 publications

Silymarin and Inflammation: Food for Thoughts

Silymarin and Inflammation: Food for Thoughts

Silybin and its congeners: from traditional medicine to molecular effects

Human Monocyte-Derived Dendritic Cells Are the Pharmacological Target of the Immunosuppressant Flavonoid Silibinin

Contact Info

Product

Resources

About